

CURRICULUM VITAE

Keith Heinzerling, MD, MPH

Pacific Neuroscience Institute
Pacific Brain Health Center
Pacific Treatment and Research in Psychedelics Program
1301 20th Street, Suite 540
Santa Monica, CA 90404
Office phone: 310-582-7612
Email: Keith.Heinzerling@providence.org

ACADEMIC APPOINTMENTS

Health Sciences Associate Professor, UCLA Department of Family Medicine	2019-current
Associate Professor in Residence, UCLA Department of Family Medicine	2013-2019
Health Sciences Assistant Clinical Professor, UCLA Department of Family Medicine	2007- 2013
Assistant Research Physician, UCLA Department of Family Medicine/ISAP	2005-2007
Chief Resident, Internal Medicine, NYU Medical Center/Bellevue Hospital	2001-2002

EDUCATION

B.A.	Human Biology, Stanford University	1988-1992
M.D.	Stanford University School of Medicine	1993-1998
Internship	Internal Medicine, NYU Medical Center/Bellevue Hospital, NY	1998-1999
Residency	Internal Medicine, NYU Medical Center/Bellevue Hospital, NY	1999-2001
Chief Resident	Internal Medicine, NYU Medical Center/Bellevue Hospital, NY	2001-2002
Fellowship	Robert Wood Johnson Clinical Scholars Program, UCLA-VAMC	2002-2005
M.P.H.	Community Health Sciences, UCLA School of Public Health	2002-2004

LICENSURE

2002-current	California Medical License (A79201)
2000-2002	New York Medical License (218195, inactive)
2004-currrent	DEA, Buprenorphine Waiver

BOARD CERTIFICATION

2001-2022	American Board of Internal Medicine, Diplomate
2009-2018	American Board of Addiction Medicine, Diplomate
2008	American Society of Addiction Medicine, Addiction Medicine Certification
2018	American Board of Addiction Medicine (Preventive Medicine), Diplomate

PROFESSIONAL EXPERIENCE

2019-current	Director, Pacific Treatment and Research in Psychedelics Program, at the Pacific Brain Health Center and Pacific Neuroscience Institute
2013-2019	Associate Professor in Residence, UCLA Department of Family Medicine
2017-current	Founder, BDH Pharmaceuticals, LLC
2017-2019	UCLA Comprehensive Chronic Pain Integrated Practice Unit, Founding Member

08/26/19

2012-2017 Medical Director, UCLA Center for Behavioral and Addiction Medicine
2007-2019 Physician, UCLA Department of Family Medicine, Addiction Medicine Program
2007-2013 Assistant Clinical Professor, UCLA Department of Family Medicine
2007-2012 Co-Investigator and Medical Director, UCLA Center for Health Promotion and Disease Prevention and UCLA Substance Abuse Pharmacotherapy Unit
2005-2007 Staff Physician, Mental Health/Substance Abuse Treatment Programs Primary Care Clinic, VA Greater Los Angeles Health Care System
2005-2007 Assistant Research Physician, UCLA Department of Family Medicine/Integrated Substance Abuse Programs

PROFESSIONAL MEMBERSHIP AND AFFILIATIONS

2000-2017 American Society of Addiction Medicine, Member
2005-2017 California Society of Addiction Medicine, Member
2002-2005 Society of General Internal Medicine, Associate Member

COMMITTEE ASSIGNMENTS/ADMINISTRATIVE SERVICE

2007-2019 UCLA Family Medicine Data Safety and Monitoring Board, Member
2011-2015 UCLA Family Medicine Patient Centered Medical Home Committee Member
2014-2017 UCLA Clinical Research Governance Committee
2015-2019 UCLA Family Medicine Council on Academic Personnel (CAP) Committee
2018-2019 UCLA Pain Management Steering Committee
2018-current UCLA High Risk Medication Work Group
2018-2019 UCLA Cannabis Research Initiative, Advisory Board

EDITORIAL WORK

2005-current Addiction, Ad hoc reviewer
2005-2007 American Journal of Preventive Medicine, Ad hoc reviewer
2005-2007 American Journal of Public Health, Ad hoc reviewer
2005-current Drug and Alcohol Dependence, Ad hoc reviewer
2005-2007 Health Services Research, Ad hoc reviewer
2010-current American Journal of Drug and Alcohol Abuse, Ad hoc reviewer
2010-current Journal of Addiction Medicine, Ad hoc reviewer
2010 Pharmacology, Biochemistry and Behavior, Ad hoc reviewer
2010 Psychiatry Research, Ad hoc reviewer
2017 Experimental and Clinical Psychopharmacology, Consulting Editor

COMMUNITY SERVICE

1999-2002 Volunteer Physician, Users Unite: Hepatitis Screening and Prevention Program for Injection Drug Users, NYU School of Medicine, New York, NY
2000-2001 Board of Directors, Lower East Side Harm Reduction Center, New York, NY
2002-2011 Board of Directors, Clean Needles Now Syringe Exchange Program, Los Angeles, CA
2008-2009 Member, Los Angeles Opioid Overdose Prevention Task Force, Los Angeles, CA
2009-2011 Member, Greater East Los Angeles Methamphetamine Task Force, Los Angeles, CA

08/26/19

- 2010 Organized Community Town Hall and Webcast on “Methamphetamine and Youth” featuring speakers and panels in East Los Angeles
- 2015-2017 Steering Committee, Los Angeles County Prescription Drug Abuse Medical Task Force
- 2016-2017 Advisory Group, California Health Care Foundation, Addiction Integration in Primary Care (APIC) Program
- 2016-2018 Co-Leader of Medication Assisted Treatment Action Team, SafeMedLA Community Opioid Task Force, California Health Care Foundation
- 2016-2017 Coach and Advisor, Treating Addiction in the Primary Care Safety Net, California Health Care Foundation

HONORS AND AWARDS

- 1993-1995 Stanford University School of Medicine, Medical Scholars Program
- 2002 American Society of Addiction Medicine, Ruth Fox Memorial Scholarship
- 2002-2005 Robert Wood Johnson Clinical Scholar
- 2003, 06-08 National Institute on Drug Abuse Extramural Loan Repayment Program
- 2008-2013 K23 Career Development Award, National Institute on Drug Abuse
- 2008 Selected as participant for NIDA Short Course on the Genetics and Epigenetics of Addiction, Bethesda, MD
- 2008 Selected as one of 25 participants in Doris Duke Foundation/Broad Institute of MIT and Harvard, Workshop on the Genetics of Complex Diseases, Boston, MA
- 2011 UCLA CTSI Maternal, Child and Adolescent Health Award for Adolescent Methamphetamine Abuse Research
- 2018 NIDA Start-up Challenge, winner of \$10,000 prize to support substance abuse start-up
- 2018-19 Top Doctors, Los Angeles Magazine (Best Addiction Medicine)
- 2019 UCLA Exceptional Physician Award

RESEARCH GRANTS AND FELLOWSHIPS

- 2002-2005 UCLA/VA Robert Wood Johnson Clinical Scholars Program, Fellowship
- 2008-2013 “Pharmacogenomics and Medication Development for Stimulant Abuse,” Principal Investigator (NIDA, K23DA023558, \$893,995)
- 2008-2009 “Pilot MRI Study of Methamphetamine Clinical Trial Participants,” Principal Investigator of Pilot Study (UCLA Center for Translational Research on Addiction, Edythe London, PI, \$10,000)
- 2009-2011 “Pilot trial of bupropion versus placebo for adolescent methamphetamine abuse,” Principal Investigator (NIDA, R21 DA026513, \$285,680)
- 2010-2013 “Phase I Safety Interaction Trial of Ibudilast with Methamphetamine,” Co-Investigator (Steven Shoptaw, PI, NIDA, R01 DA029804, \$1,178,610)
- 2011-2014 “Varenicline for Methamphetamine Dependence,” Co-Investigator (Steven Shoptaw, PI, NIDA, R01 DA030577, \$1,649,135)
- 2012-2017 “Randomized Trial of Ibudilast for Methamphetamine Dependence,” Principal Investigator (Keith Heinzerling, PI, NIDA, R01 DA035054, \$3,428,943)
- 2012-2016 “Integrated Collaborative Care for Substance Abuse Disorders,” Consultant (Katherine Watkins, PI, NIDA, R01 DA034266, \$3,226,412)
- 2013-2015 “Development of Ibudilast as a Novel Treatment for Alcoholism,” Co-Investigator (Lara Ray, PI, NIAAA, R21 AA022214, \$398,763)

08/26/19

- 2014-2016 “Adapting the HOPE Social Media Intervention to Reduce Prescription Drug Abuse,” Co-Investigator (Sean Young, PI, NIDA, R21 DA039458, \$143,980)
- 2015-2016 “Neuroinflammation and Cognitive Function in Methamphetamine Users,” Principal Investigator (Keith Heinzerling, PI, NIDA, Administrative Supplement to R01 DA035054, \$99,505)
- 2015-2018 “Combing varenicline and naltrexone for smoking cessation and drinking reduction,” Co-Investigator (Lara Ray, PI, NIDA/NIAAA, R01 DA041226, \$1,308,576)
- 2016-2019 “Phase 1 safety-interaction study of pomaglumetad methionil for methamphetamine use disorder,” Principal Investigator (Keith Heinzerling, PI, NIDA, R01 DA043238, \$3,631,094)

EDUCATIONAL ACTIVITIES

CLINICAL TEACHING ACTIVITIES

- 2008-2019 Supervision of Family Medicine Residents in UCLA Addiction Medicine Clinic
- 2008-2014 Supervision of Residents in the UCLA International Medical Graduate Training Program at the UCLA Family Health Center and UCLA Vine Street Clinic
- 2008-2009 Instructor, Clinical Skills-I, David Geffen School of Medicine at UCLA
- 2011-2015 Faculty Mentor, UCLA Addiction Medicine in Primary Care Research Fellowship (NIDA T-32)
- 2013-2016 Training and mentoring of primary care doctors at Venice Family Clinic in implementation of addiction medicine in primary care settings.
- 2016-2019 Training and mentoring of clinicians and staff at several Southern California FQHCs in the implementation of addiction medicine in primary care settings.
- 2017-current Faculty, UCLA Addiction Medicine Fellowship, UCLA Department of Family Medicine

MENTORING

- 2007 Dustin DeYoung, MD, Family Medicine-Psychiatry Resident, University of Iowa, UCLA Research Internship
- 2008 Kristen Ochoa, MD, Psychiatry Resident, Harbor/UCLA Medical Center, APA Minority Fellowship Program
- 2008 Timothy Florence, Undergraduate, University of Southern California, UCLA Research Internship
- 2008 Andrea Khosropour, UCLA Medical Student, Fourth Year Research Elective
- 2008 Holly Milne, MD, UCLA Family Medicine Resident, Research Elective
- 2009 David Chim, MD, UCLA ISAP Addiction Medicine Fellow
- 2010 Christian Kitamura, UCLA Medical Student, Short Term Training Program (STTP) Summer Research Project
- 2010 Kwokyan Tsoi, MD, UCLA Family Medicine Resident, Research Project
- 2011 David Tran, UCLA Prime MD student, Albert Schweitzer Fellow
- 2011 Shannon Connelly, MD, UCLA Family Medicine Resident, Fellowship Applicant
- 2011 Matthew Brensilver, PhD, UCLA T-32 fellow
- 2011 Shabana Tariq, MD, UCLA T-32 fellow
- 2011 Timothy Hall, MD, UCLA T-32 fellow

08/26/19

2013 Dustin DeYoung, MD, UCLA T-32 fellow
2013 Matthew Worley, PhD, UCLA T-32 fellow
2015 Joy Hao, MD, PhD, UCLA Faculty
2016 Dustin DeYoung, MD, UCLA Psychiatry faculty
2016 David Gunn, MD, UCLA Medicine faculty
2016 Karen Lamp, MD, Venice Family Clinic faculty
2016 Coley King, DO, Venice Family Clinic faculty
2016 Brian Hurley, MD, UCLA Clinical Scholar
2017 Yulsi Fernandez Montero, MD, UCLA Addiction Medicine fellow
2018 Julio Meza, MD, UCLA Addiction Medicine fellow
2019 Jon Watson, MD, UCLA Addiction Medicine fellow

LECTURES AND PRESENTATIONS

“Preventing Medical Complications of Injection Drug Use,” UCLA Addiction Psychiatry Seminar (Psychiatry 434), 2005
“Pharmacogenomics and Medication Development for Stimulant Abuse,” UCLA Addiction Psychiatry Seminar (Psychiatry 434), 2007
“Smoking Cessation in Primary Care,” Grand Rounds, UCLA Department of Family Medicine, 2007
“Medications for Methamphetamine Dependence,” Los Angeles County Probation Officers Annual Training Seminar, Los Angeles, CA, December 17, 2007
“Pharmacogenomics and Medication Development for Stimulant Abuse,” Bupropion Study Kick Off Meeting, National Institute on Drug Abuse, Bethesda, MD, April, 2008
“Smoking Cessation,” UCLA Health Care Community Health Programs, First United Methodist Church, Santa Monica, CA, July 29, 2008
“Smoking Cessation,” UCLA Arthur Ashe Student Health Center, Los Angeles, CA, October 10, 2008
“Addiction Medicine and Primary Care,” Grand Rounds, Providence Holy Cross Medical Center, Northridge, CA, February 10, 2009
“Pharmacogenomics of Smoking Cessation,” UCLA Addiction Psychiatry Seminar (Psychiatry 434), April 23, 2009
“Pain and Addiction,” Pain Management: A Multidisciplinary Approach Workshop, SEIU-UHW West and Joint Employer Education Fund, Center for Healthy Communities, Los Angeles, May 20, 2009
“Addiction Medicine and Primary Care,” Grand Rounds, Valley Presbyterian Hospital, Van Nuys, CA, June 9, 2009
“Medications for Methamphetamine Abuse,” Los Angeles Methamphetamine Task Force, West Hollywood, CA, July 29, 2009
“Medications for Methamphetamine Abuse,” Community Roundtable, City of West Hollywood, West Hollywood, CA, August 9, 2009
“Medications for Methamphetamine Abuse,” In-service, Los Angeles Gay and Lesbian Center, West Hollywood, CA, August 12, 2009
“Adolescent Substance Abuse,” In-service, Hillside, Pasadena, CA, September 30, 2009
“DTs and Aspiration Pneumonia,” Grand Rounds, Glendale Adventist Medical Center, Glendale, CA, October 23, 2009
“Addiction Medicine in Primary Care,” Grand Rounds, Hollywood Presbyterian Medical Center, Hollywood, CA, October 23, 2009

08/26/19

- “Medications for Methamphetamine Abuse,” Metro Los Angeles Crystal Meth Task Force, West Hollywood, CA, February 25, 2010
- “Smoking Cessation,” Grand Rounds, Saint Vincent Medical Center, Los Angeles, CA, March 11, 2010
- “Integration of Addiction Medicine and Primary Care,” Los Angeles County Drug and Alcohol Programs, Los Angeles, CA, April 16, 2010
- “Methamphetamine Phase II Clinical Trial Results,” NIDA P50 Centers of Excellence Meeting, Bethesda, MD, April 19, 2010
- “Ethnic Variability in COMT Polymorphisms among Methamphetamine Dependent Participants,” Pharmacogenomics in Psychiatry Meeting, New York, NY, April 23, 2010
- “Recognition and Management of Drug Dependence,” Grand Rounds, Providence Holy Cross Medical Center, January 21, 2011
- “Targeting Brain Inflammation to Treat Methamphetamine Addiction,” UCLA MDChat Community Webinar, March 6, 2014.
- “Targeting Brain Inflammation to Treat Methamphetamine Addiction,” Olive View-UCLA Medical Center, Psychiatry Grand Rounds, October 2, 2014.
- “Targeting Brain Inflammation to Treat Methamphetamine Addiction,” 11th Annual Statewide Conference: Integrating Substance Use, Mental Health, and Primary Care Services, October 23, 2014.
- “Buprenorphine Waiver Certification Training,” RAND/Venice Family Clinic, Santa Monica, April 7, 2015.
- “Medication Assisted Treatment of Opioid and Alcohol Use Disorders: Booster Training for Therapists,” RAND/Venice Family Clinic, Santa Monica, April 5, 2016
- “Treating Addiction in the Primary Care Safety Net,” California Health Care Foundation, Oakland, October 19, 2016.
- “Integrating Substance Use and Homeless Interventions in Health Homes- Medication Assisted Treatment,” California Quality Collaborative, Practice Transformation Webinar, October 20, 2016.
- “Introduction to Medication Assisted Treatment of Opioid Use Disorders in Primary Care,” JWCH Institute, Commerce, November 7, 2016.
- “Understanding the Role of Addiction in Primary Care to Combat the Opioid Epidemic: Opportunities for Partnership,” National Association of Community Health Centers (NACHC) Conference, Pasadena, November 15, 2016.
- “Office-based Treatment of Opioid Use Disorder: AAAP Buprenorphine Waiver Training,” Los Angeles County Department of Public Health, Substance Abuse Prevention and Control, Alhambra, January 5, 2017.
- “Buprenorphine Waiver Certification Training,” UCLA Department of Family Medicine, Santa Monica, March 3, 2019.
- “Impact of the Opioid Crisis on Palliative Care,” UCLA Palliative Care Conference, Los Angeles, April 5, 2019.

PUBLICATIONS/BIBLIOGRAPHY

RESEARCH PAPERS

RESEARCH PAPERS (PEER REVIEWED)

A. RESEARCH PAPERS- PEER REVIEWED

1. **Heinzerling KG**, Kral AH, Flynn NM, Anderson RL, Scott A, Gilbert ML, Asch SM, Bluthenthal RN. Unmet Need for Recommended Preventive Health Services Among Clients of California Syringe Exchange Programs: Implications for Quality Improvement. Drug and Alcohol Dependence, Volume 81, Number 2, pages 167-178, February 1, 2006.
2. **Heinzerling KG**, Etzioni DA, Hurley B, Holtom P, Bluthenthal RN, Asch SM. Hospital Utilization for Injection Drug Use-Related Soft Tissue Infections in Urban Versus Rural Counties in California. Journal of Urban Health, Volume 83, Number 2, pages 176-181, March 2006.
3. **Heinzerling KG**, Shoptaw S, Peck JA, Yang X, Liu J, Ling W. Randomized, Placebo-Controlled Trial of Baclofen and Gabapentin for the Treatment of Methamphetamine Dependence. Drug and Alcohol Dependence, Volume 85, Number 3, pages 177-184, December 1, 2006.
4. **Heinzerling KG**, Kral AH, Flynn NM, Anderson RL, Scott A, Gilbert ML, Asch SM, Bluthenthal RN. HIV and Hepatitis C Testing at Syringe Exchange Programs: Availability and Outcomes. Journal of Substance Abuse Treatment, Volume 32, Number 4, pages 423-429, June 2007.
5. Bluthenthal RN, **Heinzerling KG**, Gilbert ML, Anderson R, Flynn NM, Scott A, Kral AH. Legalization of syringe exchange programs in California: Mixed results from a local approach to HIV prevention. American Journal of Public Health, Volume 98, Number 2, pages 278-83, February 2008.
6. Shoptaw S, **Heinzerling KG**, Rotheram-Fuller E, Kao UH, Wang PC, Bholat M, Ling W. Bupropion Hydrochloride Versus Placebo, in Combination with Cognitive Behavioral Therapy, for the Treatment of Cocaine Abuse/Dependence. Journal of Addictive Diseases, Volume 27, Number 1, pages 13-23, February 2008.
7. Shoptaw S, **Heinzerling KG**, Rotheram-Fuller E, Steward T, Wang PC, Swanson AN, De La Garza R, Newton T, Ling W. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, Volume 96, Number 3, pages 222-32, August 1, 2008.
8. Dean AC, London ED, Sugar CA, Kitchen CMR, Swanson A, **Heinzerling KG**, Kalechstein AD, Shoptaw S. Predicting Adherence to Treatment for Methamphetamine Dependence from Neuropsychological and Drug Use Variables. Drug and Alcohol Dependence, Volume 105, Numbers 1-2, pages 48-55, November 1, 2009.
9. Shoptaw SJ, Kao U, **Heinzerling K**, Ling W. Treatment for amphetamine withdrawal. Cochrane Database of Systematic Reviews, April 15, 2009; (2):CD003021.

10. De La Garza R 2nd, Zorick T, **Heinzerling KG**, Nusinowitz S, London ED, Shoptaw S, Moody DE, Newton TF. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. Pharmacology Biochemistry and Behavior, Volume 94, Number 1, pages, 186-93, November 2009.
11. **Heinzerling KG**, Swanson AN, Kim S, Cederblom L, Moe A, Ling W, Shoptaw S. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, Volume 109, Numbers 1-3, pages 20-9, June 1, 2010.
12. Heslin KC, Stein JA, **Heinzerling K**, Pan D, Magladry C, Hays RD. Clinical correlates of health-related quality of life among opioid-dependent patients. Quality of Life Research, Volume 20, Number 8, pages 1205-13, October 2011.
13. Ling W, Shoptaw S, Hillhouse M, Bholat MA, Charuvastra C, **Heinzerling K**, Chim D, Annon J, Dowling PT, Doraimani G. Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence. Addiction, Volume 107, Number 2, pages 361-9, February 2012.
14. **Heinzerling KG**, Shoptaw S. Gender, BDNF Val66Met, and Methamphetamine Use Frequency. Gender Medicine, Volume 9, Number 2, pages 112-20, April 2012.
15. Brensilver M, **Heinzerling KG**, Swanson AN, Shoptaw SJ. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug and Alcohol Dependence, electronic publication April 23, 2012.
16. Brensilver M, **Heinzerling KG**, Swanson AN, Shoptaw SJ. Placebo-Group Responders in Methamphetamine Pharmacotherapy Trials: The Role of Immediate Establishment of Abstinence. Experimental and Clinical Psychopharmacology, Volume 20, Number 5, pages 430-5, October 2012.
17. Brensilver M, **Heinzerling KG**, Swanson AN, Telesca D, Furst BA, Shoptaw SJ. Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. Drug and Alcohol Review, Volume 32, Number 1, pages 96-9, January 2013.
18. **Heinzerling KG**, Gadzhyan J, van Oudheusden H, Rodriguez F, McCracken J, Shoptaw S. Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. Journal of Adolescent Health, Volume 52, Number 4, pages 502-5, April 2013.
19. Brensilver M, **Heinzerling KG**, Shoptaw SJ. Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug and Alcohol Review, Number 32, Volume 5, pages 449-60, September 2013.
20. Swanson AN, Shoptaw S, **Heinzerling KG**, Wade AC, Worley M, McCracken J, Wilson SA, Asarnow J, London ED. Up in smoke? A preliminary open-label trial of nicotine replacement therapy and cognitive behavioral motivational enhancement for smoking cessation among youth in Los Angeles. Substance Use and Misuse, Volume 48, Number 14, pages 1553-62, December 2013.

21. **Heinzerling KG**, Swanson AN, Hall T, Yi Y, Wu Y, Shoptaw S. Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. *Addiction*, Volume 109, Number 11, pages 1878-86, November 2014.
22. Ray LA, Roche DJ, **Heinzerling K**, Shoptaw S. Opportunities for the development of neuroimmune therapies in addiction. *Int Rev Neurobiol*, Volume 118, pages 381-401, September 2014.
23. Thames AD, Briones MS, Magpantay LI, Martinez-Maza O, Singer EJ, Hinkin CH, Morgello S, Gelman BB, Moore DJ, **Heinzerling K**, Levine AJ. The role of chemokine C-C motif ligand 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients. *AIDS*. Volume 29, Number 12, pages 1483-91, July 31, 2015.
24. Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, Leventhal A, Shoptaw S, **Heinzerling K**, London ED, Miotto K. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: A Double-Blind, Placebo-Controlled Laboratory Study. *Neuropsychopharmacology*, Volume 40, Number 10, pages 2347-56, September 2015.
25. Worley MJ, **Heinzerling KG**, Shoptaw S, Ling W. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain. *Exp Clin Psychopharmacol*, Volume 23, Number 6, pages 428-35, December 23, 2015.
26. **Heinzerling KG**, Demirdjian L, Wu Y, Shoptaw S. Single nucleotide polymorphism near CREB1, rs7591784, is associated with pretreatment methamphetamine use frequency and outcome of outpatient treatment for methamphetamine use disorder. *J Psychiatr Res*, Volume 74, pages 22-9, March, 2016.
27. Worley MJ, **Heinzerling KG**, Roche DJ, Shoptaw S. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. *Drug Alcohol Depend*, Volume 162, pages 245-50, May 1, 2016.
28. DeYoung DZ, **Heinzerling KG**, Swanson AN, Tsuang J, Furst BA, Yi Y, Wu YN, Moody DE, Andrenyak DM, Shoptaw SJ. Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment. *J Clin Psychopharmacol*, June 6, 2016.
29. Young SD, **Heinzerling K**. The Harnessing Online Peer Education (HOPE) Intervention for Reducing Prescription Drug Abuse: A Qualitative Study. *J Subst Use*, Volume 22, Number 6, pages 592-96, January 31, 2017.
30. Ray LA, Bujarski S, Shoptaw S, Roche DJ, **Heinzerling K**, Miotto K. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. *Neuropsychopharmacology*, Volume 42, Number 9, pages 1776-88, August, 2017.
31. Cook R, Quinn B, **Heinzerling K**, Shoptaw S. Dropout in clinical trials of pharmacologic treatment for methamphetamine dependence: the role of initial abstinence. *Addiction*, Volume 112, Number 6, pages 1077-85, June 2017.

32. Worley MJ, **Heinzerling KG**, Shoptaw S, Ling W. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. *Addiction*, Volume 112, Number 7, pages 1202-09, July 2017.
33. Birath JB, Briones M, Amaya S, Shoptaw S, Swanson AN, Tsuang J, Furst B, **Heinzerling K**, Obermeit L, Maes L, McKay C, Wright MJ. Ibutilast may improve attention during early abstinence from methamphetamine. *Drug Alcohol Depend*, Volume 178, pages 386-90, September 1, 2017.
34. Watkins KE, Ober AJ, Lamp K, Lind M, Setodji C, Osilla KC, Hunter SB, McCullough CM, Becker K, Iyiewuare PO, Diamant A, **Heinzerling K**, Pincus HA. Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care: The SUMMIT Randomized Clinical trial. *JAMA Intern Med*, Volume 177, Number 10, pages 1480-88, October 1, 2017.
35. Bachtell RK, Jones JD, **Heinzerling KG**, Beardsley PM, Comer SD. Glial and neuroinflammatory targets for treating substance use disorders. *Drug Alcohol Depend*, Volume 180, pages 156-70, November 1, 2017.
36. Ober AJ, Watkins KE, Hunter SB, Ewing B, Lamp K, Lind M, Becker K, **Heinzerling K**, Osilla KC, Diamant AL, Setodji CM. Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study. *BMC Family Practice*, Volume 18, Number 1, page 107, December 21, 2017.
37. Watkins KE, Ober AJ, Lamp K, Diamant A, Osilla KC, **Heinzerling K**, Hunter SB, Pincus HA. Implementing the Chronic Care Model for Opioid and Alcohol Use Disorders in Primary Care. *Prog Community Health Partnersh*, Volume 11, Number 4, pages 397-407, 2017.
38. Severino AL, Shadfar A, Hakimian JK, Crane O, Singh G, **Heinzerling K**, Walwyn WM. Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic. *Front Psychiatry*. Volume 9, page 199, April 23, 2018.
39. Briones M, Shoptaw S, Cook R, Worley M, Swanson AN, Moody DE, Fang WB, Tsuang J, Furst B, **Heinzerling K**. Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial. *Drug Alcohol Depend*. Volume 189, pages 30-36, May 25, 2018.
40. Young SD, Koussa M, Lee SJ, Perez H, Gill N, Gelberg L, **Heinzerling K**. Feasibility of a social media/online community support group intervention among chronic pain patients on opioid therapy. *J Addict Dis*. 2018 Jan-Jun;37(1-2):96-101.

B. RESEARCH PAPERS- PEER REVIEWED (IN PRESS)

None.

C. RESEARCH PAPERS- PEER REVIEWED (SUBMITTED)

1. Young SD, Lee SJ, Koussa M, Perez H, Gill N, Gelberg L, **Heinzerling K**. Somatization, Mental Health and Pain Catastrophizing Factors Associated with Opioid Misuse among Patients with Chronic Non-Cancer Pain.

2. Heinzerling K, Briones M, Thames AD, Hinkin CH, Zhu T, Wu YN, Shoptaw SJ. Randomized, placebo-controlled trial of targeting neuroinflammation with ibudilast to treat methamphetamine use disorder.

RESEARCH PAPERS- NON-PEER REVIEWED

D. RESEARCH PAPERS – NON-PEER REVIEWED

1. Longshore D, Santiago L, **Heinzerling K**. Harm Reduction Primary Care Program Evaluation. Los Angeles, CA: University of California at Los Angeles, January 2003.
2. **Heinzerling KG**, Ober AJ, Lamp K, De Vries D, Watkins KE. SUMMIT: Procedures for Medication-Assisted Treatment of Alcohol or Opioid Dependence in Primary Care. Santa Monica, CA: RAND Corporation, 2016.
3. Ober AJ, Watkins KE, Lamp K, Lind M, Osilla K, **Heinzerling K**, De Vries D, Iyiewuare P, Diamant A. SUMMIT Study Protocol - REVISED: Step-by-Step Procedures for Providing Screening, Brief Intervention, and Treatment Services to Primary Care Patients with Alcohol or Opioid Use Disorders. Santa Monica, CA: RAND Corporation, 2016.

E. RESEARCH PAPERS- NON-PEER REVIEWED (IN PRESS)

None

F. RESEARCH PAPERS- NON-PEER REVIEWED (SUBMITTED)

None

CHAPTERS

1. Shoptaw S, King WD, Landstrom E, Bholat MA, **Heinzerling KG**, Roll J. Medical Consequences of Methamphetamine Dependence. Chapter in Methamphetamine Addiction: From Basic Science to Treatment, edited by Roll JM, Rawson RA, Ling W, Shoptaw S. The Guilford Press, May 24, 2009.
2. **Heinzerling K**. Medication Development for Amphetamine Dependence. Chapter in Encyclopedia of Addictive Behaviors, edited by Miller P. Academic Press, May 15, 2012.
3. **Heinzerling K**. Applying best practice guidelines on chronic pain in clinical practice—treating patients who suffer from pain and addiction. Chapter in The Assessment and Treatment of Addiction: Best Practices and New Frontiers, First Edition, edited by Danovitch I, Mooney L. Elsevier, September 15, 2018.

LETTERS TO THE EDITOR

1. **Heinzerling KG**, McCracken JT, Swanson AN, Ray LA, Shoptaw SJ. COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. Journal of Clinical Psychopharmacology, Volume 32, Number 1, pages 135-7, February 2012.

REVIEWS

None

EDITORIALS

1. Bluthenthal RN, **Heinzerling KG**, Martinez A, Kral AH. Police Crackdowns, Societal Cost, and the Need for Alternative Approaches. International Journal of Drug Policy, Volume 16, Issue 3, pages 137-138, June 2005.

PAPERS IN PREPARATION (RESEARCH COMPLETED)

None

ABSTRACTS AND CONFERENCE PRESENTATIONS

1. **Heinzerling K**, Shalev N, Triola M. Brief Intervention to Reduce Harmful Injection Practices Among Injection Drug Users in Health Care Settings, Harm Reduction Coalition, 4th National Conference, Seattle, WA, Dec. 2002.
2. Kluger MD, **Heinzerling KG**, Shalev N, Capponi L. Designing a Clinical Hepatitis Screening and Prevention Program for a Needle Exchange, Harm Reduction Coalition, 4th National Conference, Seattle, WA, Dec. 2002.
3. Ochoa KC, Hair TL, **Heinzerling K**, Hyde J. Abscesses and Cellulitis are Common Among Injection Drug Users Attending a Needle Exchange Program, American Public Health Association, 131st Annual Meeting, San Francisco, CA, Nov. 2003.
4. **Heinzerling K**, Nakazono T, Shapiro M, Cunningham W. Are Drug Users Different? Comparison of Factors Associated with Highly Active Antiretroviral Therapy Among HIV Positive Injection Drug Users and Non-Users, Robert Wood Johnson Clinical Scholars Program, National Meeting, Ft. Lauderdale, FL, Nov. 2003.
5. **Heinzerling KG**, Flynn NM, Kral AH, Anderson RL, Asch SM, Bluthenthal RN. Comprehensive Health Care for Substance Using Populations: Syringe Exchange Programs and Preventive Services for IDUs, The Central Point Conference, California Department of Health Services Office of AIDS, Sacramento, February 2004.
6. **Heinzerling KG**, Flynn NM, Kral AH, Anderson RL, Asch SM, Bluthenthal RN. The Role of Syringe Exchange Programs in the Delivery of Preventive Health Services to Injection Drug Users, Society of General Internal Medicine, Annual Meeting, Chicago, May 13-15, 2004.
7. **Heinzerling KG**, Flynn NM, Kral AH, Anderson RL, Asch SM, Bluthenthal RN. The Role of Syringe Exchange Programs in the Delivery of Preventive Health Services to Injection Drug Users, NIDA/NIAAA/NIMH, Complexities of Co-occurring Conditions Conference, Washington, D.C., June 23-25, 2004.
8. Hurley B, Ochoa K, **Heinzerling K**, Holtom P. Injection Drug Use and Health Service Utilization Associated with Soft Tissue Infection Admissions at Los Angeles County/USC Medical Center, Harm Reduction Coalition, 5th National Conference, New Orleans, LA, November 11-14, 2004.
9. Ochoa K, Fernandez M, Scholar S, Hair T, Lopez B, Triola M, **Heinzerling K**. Building a Successful Needle Exchange Website, Harm Reduction Coalition, 5th National Conference, New Orleans, LA, November 11-14, 2004.

10. **Heinzerling KG**, Flynn NM, Kral AH, Anderson RL, Asch SM, Bluthenthal RN. The Quality of Preventive Health Services Received by Injection Drug Users Using Syringe Exchange Programs in California, Harm Reduction Coalition, 5th National Conference, New Orleans, LA, November 11-14, 2004.
11. **Heinzerling KG**, Flynn NM, Kral AH, Anderson RL, Asch SM, Bluthenthal RN. The Quality of Preventive Health Services Received by Injection Drug Users Using Syringe Exchange Programs in California, Robert Wood Johnson Clinical Scholars Program, National Meeting, Phoenix, AZ, November 10-13, 2004.
12. Shoptaw S, Rotheram-Fuller E, **Heinzerling K**, Wang J, Ling W. "Contingency management as a strategy for recruiting participants into clinical trials," CPDD 69th Annual Scientific Meeting, Quebec City, Canada, June 17-23, 2007.
13. Kahn R, Shoptaw S, Elkashef A, Childress AR, Fudala P, Gorgon L, Kilby S, Biswas K, **Heinzerling K**. "A Randomized, Double-blind, Placebo-controlled Multi-center Trial of Baclofen for the Treatment of Cocaine Dependence," CPDD 69th Annual Scientific Meeting, Quebec City, Canada, June 17-23, 2007.
14. **Heinzerling KG**, Shoptaw S, Swanson A, Rotheram-Fuller E. "Factors associated with cognitive dysfunction among methamphetamine users," CPDD 70th Annual Scientific Meeting, San Juan, Puerto Rico, June 14-19, 2008.
15. Shoptaw S, **Heinzerling KG**, Rotheram-Fuller E, Steward T, Wang J, Swanson A, DeLaGarza R, Newton T, Ling W. "Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence," CPDD 70th Annual Scientific Meeting, San Juan, Puerto Rico, June 14-19, 2008.
16. Dean AC, London ED, Sugar CA, Kitchen CMR, Swanson A, **Heinzerling KG**, Kalechstein AD, Shoptaw S. "Predicting Adherence to Treatment for Methamphetamine Dependence from Neuropsychological and Drug Use Variables," CPDD 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.
17. Florence TJ, **Heinzerling KG**, Swanson A, Shoptaw S. "Methamphetamine-related versus Cocaine-related Emergency Department Visits in Rural versus Urban Counties in California," CPDD 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.
18. **Heinzerling KG**, Shoptaw S, Swanson A, Ling W. "Randomized, double-blind trial of modafinil versus placebo for methamphetamine dependence," CPDD 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.
19. **Heinzerling KG**, Ray L, Swanson A, Shoptaw S. "Ethnic variation in COMT polymorphisms among Caucasian and Hispanic methamphetamine users," Psychiatric Pharmacogenomics Conference, New York, NY, April 23, 2010.
20. **Heinzerling KG**, Shoptaw S, Swanson A, Ling W. "Cognitive dysfunction is associated with early drop-out in treatment for methamphetamine dependence," CPDD 72nd Annual Scientific Meeting, Scottsdale, AZ, June 12-17, 2010.

21. Swanson A, Shoptaw S, **Heinzerling K**. “Varenicline for the treatment of methamphetamine dependence: A pilot study,” CPDD 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.
22. Brensilver M, Telesca D, Swanson A, **Heinzerling K**, Shoptaw S. “Cigarette smoking as a target for potentiating outcomes for methamphetamine use treatment,” CPDD 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.
23. **Heinzerling KG**, McCracken J, Ray L, Swanson A, Shoptaw S. “Preliminary pharmacogenetic study of treatment for methamphetamine dependence,” CPDD 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.
24. Tran D, Rodriguez F, van Oudheusden H, **Heinzerling KG**. “Exposure to Drug-related ‘People, Places, and Things’ via Online Social Networking Sites Among Adolescents in Substance Abuse Treatment,” American Psychiatric Association Annual Meeting, Philadelphia, PA, May 5-9, 2012.
25. **Heinzerling KG**, Hall T, Swanson A, Shoptaw S. “Randomized trial of bupropion in methamphetamine dependent participants with less than daily methamphetamine use,” CPDD 75th Annual Scientific Meeting, San Diego, CA, June 15-20, 2013.
26. Swanson A, Wright M, Birath JB, Tsuang J, Furst B, **Heinzerling K**, Obermeit LC, Amaya S, Maes L, McKay C, Shoptaw S. “Ibuprofen may reduce inattention associated with methamphetamine use,” CPDD 75th Annual Scientific Meeting, San Diego, CA, June 15-20, 2013.
27. Hauser K, Beardsley P, Comer S, Shoptaw S, **Heinzerling K**. “Preclinical to clinical evidence that glia and neuroinflammation mediate drug abuse and related pathologies,” CPDD 75th Annual Scientific Meeting, San Diego, CA, June 15-20, 2013.
28. DeYoung D, **Heinzerling K**, Swanson AN, Tsuang J, Furst B, Yi Y, Wu YN, Shoptaw S. “Cardiovascular safety of ibuprofen treatment with intravenous methamphetamine administration,” CPDD 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.
29. Worley M, **Heinzerling K**, Shoptaw S, Ling W. “Chronic pain volatility predicts outcomes of buprenorphine-naloxone for prescription opioid dependence,” CPDD 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.
30. Briones M, Worley M, DeYoung D, Swanson A, **Heinzerling KG**, Shoptaw S. “Varenicline for the treatment of methamphetamine dependence,” CPDD 77th Annual Scientific Meeting, Phoenix, AZ, June 13-18, 2015.
31. **Heinzerling K**. “Are new clinical trial designs needed for the successful translation of research into an effective medication for stimulant dependence?” CPDD 77th Annual Scientific Meeting, Phoenix, AZ, June 13-18, 2015.
32. **Heinzerling K**, Demirdjian L, Briones M, Swanson A, Wu Y, Shoptaw S. “Association of gender and genetic ancestry with frequency of methamphetamine use among methamphetamine-dependent Hispanic and Non-Hispanic Whites,” CPDD 77th Annual Scientific Meeting, Phoenix, AZ, June 13-18, 2015.

33. Demirdjian L, Wu Y, Shoptaw S, **Heinzerling K.**” Candidate gene study of methamphetamine use frequency among methamphetamine dependent Hispanic and Non-Hispanic Whites,” 14th Annual Pharmacogenetics in Psychiatry Meeting, Toronto, ON, October 15, 2015.
34. Bachtell RK, Beardsley PM, **Heinzerling KG**, Comer SD. “Plenary symposium: “Glial and neuroinflammatory targets for treating substance use disorders,” Behavior, Biology and Chemistry (BBC): Translational Research in Addiction, San Antonio, TX, March 5, 2016.

PATENTS AND INTELLECTUAL PROPERTY

1. Treatment of Opioid Use Disorder, Opioid Withdrawal Symptoms, and Chronic Pain. U.S. Provisional Patent Application No. 62/586,636, Applicant: The Regents of the University of California, Inventors: **Heinzerling K**, Briones M, DeYoung D, Filing Date: November 15, 2017.